- Home
- ZLAB vs SIGA Comparison
ZLAB vs SIGA Comparison
Compare ZLAB & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | SIGA |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 462.6M |
| IPO Year | 2017 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | SIGA |
|---|---|---|
| Price | $18.34 | $6.27 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $57.22 | N/A |
| AVG Volume (30 Days) | ★ 937.7K | 327.3K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 9.57% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $441,629,000.00 | $172,249,641.00 |
| Revenue This Year | $26.16 | N/A |
| Revenue Next Year | $30.62 | $132.36 |
| P/E Ratio | ★ N/A | $6.09 |
| Revenue Growth | ★ 24.14 | N/A |
| 52 Week Low | $16.82 | $4.95 |
| 52 Week High | $44.34 | $9.62 |
Technical Indicators
Market Signals| Indicator | ZLAB | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 45.49 |
| Support Level | $17.37 | $6.20 |
| Resistance Level | $19.01 | $6.45 |
| Average True Range (ATR) | 0.63 | 0.16 |
| MACD | 0.31 | 0.05 |
| Stochastic Oscillator | 57.51 | 39.76 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.